Immunome (IMNM) Capital Expenditures (2019 - 2026)

Immunome (IMNM) has 8 years of Capital Expenditures data on file, last reported at $3.0 million in Q1 2026.

• Quarterly Capital Expenditures fell 18.09% year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.0 million (down 11.93% YoY) and the FY2025 annual result came in at $9.7 million, up 35.02% from the prior year.
• Capital Expenditures slipped to $3.0 million in Q1 2026, from $4.0 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $4.4 million in Q3 2025 to a low of -$2.4 million in Q2 2025.
• A 5-year average of $1.3 million and a median of $408500.0 in 2023 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2023 — Capital Expenditures soared 3616.67% — and 2025, when it plunged 160.76%.
• Tracing IMNM's Capital Expenditures over 5 years: stood at $72000.0 in 2022, then declined by 20.83% to $57000.0 in 2023, then soared by 1875.44% to $1.1 million in 2024, then jumped by 255.15% to $4.0 million in 2025, then decreased by 24.93% to $3.0 million in 2026.
• The last three Capital Expenditures figures came in at $3.0 million (Q1 2026), $4.0 million (Q4 2025), and $4.4 million (Q3 2025), per Business Quant data.